Cornerstone Pharmaceutical-B (02616) released interim results, with revenue of 205 million yuan, a significant year-on-year increase of 314.75%

According to the Zhitong Finance App, Cornerstone Pharmaceutical-B (02616) announced interim results for the six months ended June 30, 2026. The group obtained revenue of RMB 205 million (same unit), an increase of 314.75% over the previous year; loss of 252 million yuan during the period, a year-on-year decrease of 6.62%; and a loss of 0.17 yuan per share.

According to the announcement, revenue includes $183 million from drug sales (avatinib, platinib and sugarizumab), $6.9 million from licensing fees, and $15 million from licensing fees. The sharp increase in revenue was mainly driven by a significant increase in sales of pharmaceuticals (especially platinib). This was due to the drug being successfully included in the National Medical Insurance Drug Catalogue (National Health Insurance Catalogue) from January 2026, which led to a significant increase in sales.

The core of our strategy is to achieve sustainable growth by advancing Pipeline 2.0 globally and maximizing the life cycle value of our marketed products. We implement this strategy through a capital-efficient and asset-light model, prioritizing internal resources on core competencies: early detection, translational science, and clinical development. Through partnerships with leading contract research organizations (CRO) and contract development and manufacturing organizations (CDMO), we are able to maintain operational flexibility without compromising scientific rigor. We drive commercialization through strategic partnerships in key regional markets to expand patient coverage and drive revenue growth while maintaining a high focus on innovation. Looking ahead, we will continue to strengthen our research and clinical capabilities, push high-potential assets into the later stages of development, and adopt tailored global cooperation strategies to maximize the value of our commercial product portfolio and pipeline.